AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01144949 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: one placebo capsule orally, once daily, with food for up to 4 weeks
Study NCT04550650 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training groupe
Description: Using virtual training
Study NCT04550650 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF
Description: PNF technique was used
Study NCT04550650 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinning grp
Description: They only worked with spinning bikes.
Study NCT04550650 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance
Description: Balance development was done
Study NCT02008292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Physostigmine
Description: All subjects will receive physostigmine to induce elevated ACh levels in the brain.
Study NCT00088465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intramuscular olanzapine depot
Description: 45-405 milligram (mg), intramuscular injection, on a 2-, 3-, or 4-week interval.
Study NCT00495469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK189075
Description: GSK189075 is available as a white, capsule-shaped tablet dosage form containing 50mg, 125mg, 250mg or 500mg of GSK189075 per tablet
Study NCT00495469 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Available as Placebo matching tablet to GSK189075
Study NCT01390857 — intervention group
Intervention type: DRUG
Intervention: Valaciclovir
Study NCT04138628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: The study drug will be given according to current recommendations as systemic treatment every third week for 12 months or until progression. Treatment will be initiated within 28 days of detection of ctDNA.
Study NCT01123161 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hypothermia and anti-shivering treatment
Description: Hypothermia is induced using the Celsius Control™ System. Shivering is treated with buspirone, meperidine and surface warming
Study NCT01123161 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group1: IV t-PA and normothermia
Description: Group 1 will t-PA as standard of care and normothermia
Study NCT03450876 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional
Study NCT04294082 — intervention group
Intervention type: BEHAVIORAL
Intervention: Mindfulness based intervention
Description: A four session, 120 mins per session mindfulness based course delivered weekly oer the course of four weeks. The mindfulness sessions are based on the model delineated by Kabat-Zinn (1992) and will encompass:~* an introduction to mindfulness~* body-scan exercises~* sitting meditation~* mindful movement exercises~* individual and group reflections~* homework exercises
Study NCT02723851 — intervention group
Intervention type: DEVICE
Intervention: Corsens
Description: Recording and calculating Peak Endocardial Acceleration (PEA) Myocardial Contractility Index \[MCI\] and isovolumetric contraction (IVCT). Measurements will not affect the treatment provided to the patients.
Study NCT02055482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molidustat (BAY85-3934)
Description: BAY85-3934 will be titrated at the scheduled dose control visits to maintain the Hb in the target range of 10.0 to 12.0 g/dL. Available doses include 15, 25, 50, 75, 100, and 150 mg/day OD. Treatment will be for minimum of 6 months to up to a maximum of 36 months.
Study NCT02055482 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin
Description: Darbepoetin will be administered according to the local label and titrated at the scheduled dose by intravenous injection. Treatment will be for a minimum of 6 months to up to a maximum of 36 months.
Study NCT01497444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hypoxia-activated prodrug TH-302
Study NCT01497444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Study NCT04550156 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colorectal Bundle
Description: 1. Preoperative optimization of the nutritional status: Perform nutritional risk screening (NRS), measure albumin or prealbumin preoperatively and initiate nutritional support~2. Preoperative showering with an antiseptic agent~3. Administer preoperative antibiotic prophylaxis~4. Hair removal in the operative field with clippers~5. Peri-, intra-, and postoperative warming to maintain body temperature~6. Peri- and intraoperative glucose control~7. Usage of a wound protection device~8. Change of gloves and instruments after anastomosis~9. Anastomosis only with experienced senior surgeon present in theatre for any elective and emergency procedures
Study NCT03743610 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo simulated altitude
Description: Participants will exercise at sea level at similar percentage of intensities to the simulated altitude group.
Study NCT02571803 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary And Lifestyle Counseling
Description: The DASH (Dietary Approaches to Stop Hypertension) diet is a dietary pattern of proven effect on arterial blood pressure reduction. It is rich in fruits, vegetables, whole grains, and low-fat dairy foods; includes meat, fish, poultry, nuts, and beans; and is limited in sugar-sweetened foods and beverages, red meat, and added fats. Dietary counseling will be provided during each of 7 control visits within the 12-month time of observation.
Study NCT02571803 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimal Medical Treatment
Description: Optimal Medical Treatment as per 2013 ESC Guidelines on the Management of Stable Coronary Artery Disease.
Study NCT02571803 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optimal Medical Treatment
Description: Optimal Medical Treatment as per 2013 ESC Guidelines on the Management of Stable Coronary Artery Disease.
Study NCT00590694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: 0.5mg injection monthly according to protocol for one year
Study NCT02573285 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Simple Aspiration
Description: Aspiration of pneumothorax with a small-bore catheter
Study NCT02170519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Iloprost
Description: A 20 mcg dose of Iloprost will be given initially.
Study NCT03342222 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Interference Screws
Description: tibial fixation for ACL reconstruction
Study NCT03342222 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interference Screws
Description: tibial fixation for ACL reconstruction
Study NCT01285232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: 150 mg sc once daily during four weeks
Study NCT01285232 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anakinra
Description: 150 mg sc once daily during four weeks
Study NCT00835354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefprozil for oral suspension 250 mg/5 mL
Description: 1 x 250 mg/5 mL, single-dose fasting
Study NCT00835354 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CEFZIL® for Oral Suspension 250 mg/5mL
Description: 1 x 250 mg/5 mL, single-dose fasting
Study NCT02302222 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Customizable Dressing with ActiV.A.C. Therapy Unit
Study NCT02302222 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Dressing
Study NCT03095911 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: News items with spin
Description: Interpretation of news items with spin
Study NCT04666675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral; Tablet
Study NCT04666675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Upadacitinib
Description: Oral; Tablet
Study NCT04603612 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Primary TURBT
Description: As shown in (Fig. 1), all patients will be thoroughly evaluated by medical history and physical exam, laboratory investigations, abdominal pelvic ultrasound (US). Then, all patients will be managed by cystoscopy and initial complete TURBT. Patients with benign pathology, non-urothelial carcinoma or muscle invasive disease, will be excluded from the study.~After 4-6 weeks, eligible patients will be appointed for repeat resection TURBT.
Study NCT02286583 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Microwave Thermography RTM-01-RES
Description: Divide the breast into 3 circles start from the nipple with 1 cm increase in the circle diameter. Divide this circle into 8 points. This makes us detect 24 points in addition to the nipple as fixed point and the tail of the breast as separate point giving total of 26 points.
Study NCT00902668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lovastatin
Study NCT00902668 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Study NCT00902668 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Study NCT00902668 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: accelerated partial breast irradiation
Study NCT00902668 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: external beam radiation therapy
Study NCT01967433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Study NCT01967433 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01925274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05212384
Description: 30 minute IV infusion of PF-05212384 on days 2, 9, 16 and 23 of each cycle. Intra-patient dose escalation will commence with 110mg and will increase depending on tolerability.
Study NCT01925274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: 90 minutes IV infusion of irinotecan 180mg/m\^2 on days 1 and 15 of each cycle
Study NCT01925274 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: 120 minute IV infusion of cetuximab 400mg/m\^2 on cycle 1 day 1; 60 minute IV infusion of cetuximab on days 8, 15, and 22 of each cycle, and on day 1 of each cycle after cycle 1
Study NCT01925274 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: 90 minutes IV infusion of Irinotecan 180mg/m\^2 on days 1 and 15 of each cycle
Study NCT00057954 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Photopheresis
Description: Day -7 to -4: Extracorporeal Photopheresis may be given as an outpatient therapy on two consecutive days any time between days -7 to -4. This must be performed on UVAR or XTS photopheresis machines (Therakos, Inc.) according to standard procedure as per manufacturer's guidelines.
Study NCT02573285 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgeon Preference
Description: Any standard treatment option may be utilized for the treatment of the pneumothorax, including simple aspiration, chest tube placement, or an operation (VATS).
Study NCT00057954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentostatin
Description: Day -3, -2: Pentostatin 4 mg/m²/d by continuous IV infusion (Total dose = 8 mg/m²)
Study NCT00057954 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation (TBI)
Description: Day -1: TBI 400 cGy total dose given in two 200cGy doses. Patients who have received TBI for a previous transplant or radiation as part of previous treatment for a lymphoid malignancy will receive only 200 cGy in 1 dose.
Study NCT00057954 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplantation
Description: Day 0: Infusion of unmanipulated allogeneic bone marrow or stem cells. Minimum cell dose of 2 x 106 CD34 cells/kg recipient and no more than 10 x 10\^6 CD34/kg
Study NCT00057954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporin (CSA)
Description: Cyclosporin A or tacrolimus will be administered according to institutional GVHD prophylaxis protocols. Therapeutic levels will be maintained and patients will be switched to oral agents when they can tolerate
Study NCT00057954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Description: At day 100 MMF will be introduced at a dose of 250 mg po BID and cyclosporine or tacrolimus will be tapered according to the discretion of the investigator. The dosage will be escalated to a maximum of 2 g/d at the discretion of the attending physician and will be tapered and discontinued at 12 months if there is no active cGVHD. Doses should be given on an empty stomach
Study NCT00057954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Description: The dose of Methotrexate is based on the corrected ideal body weight for patients with > 33% above ideal weight.~Day +1 MTX 15 mg/m² IV push; Day +3 MTX 10 mg/m² IV push (May be omitted if patient develops mouth sores.)
Study NCT03237832 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ARN-6039
Description: Ascending doses per Cohort
Study NCT00559754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 15mg/kg iv on day 1 of each 3 week cycle
Study NCT00559754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75mg/m2 iv on day 1 of each 3 week cycle
Study NCT00559754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard chemotherapy
Description: As prescribed
Study NCT00333177 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive remediation training (CT)
Description: Cognitive remediation training includes computerized cognitive training plus learning skills group.
Study NCT03095911 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: News items without spin
Description: Interpretation of news items without spin
Study NCT03237832 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match ARN-6039
Study NCT03408496 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial release
Description: Manual therapy
Study NCT03408496 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle stretching
Description: Muscle stretching
Study NCT03408496 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Medical appointment
Study NCT03166436 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: radiofrequency ablation
Study NCT03166436 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biliary stenting
Description: biliary stenting
Study NCT03166436 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biliary stenting
Description: biliary stenting
Study NCT03095950 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: News items with spin
Description: Interpretation of news items with spin
Study NCT03095950 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: News items without spin
Description: Interpretation of news items without spin
Study NCT02376257 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 250 mg DCS
Description: Drug
Study NCT02376257 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100 mg Modafinil
Description: Drug
Study NCT02376257 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug
Study NCT03346850 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric tube (NGT) feeding
Description: A nasogastric tube goes from the nose to the stomach.
Study NCT03346850 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasoduodenal tube (NDT) feeding
Description: A nasoduodenal tube goes from the nose to the duodenum.
Study NCT01104948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-8031
Study NCT01104948 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04440709 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brain/neural hand exoskeleton (B/NHE)
Description: The brain/neural hand exoskeleton restores hand motor function by translating user's intention into grasping motions
Study NCT04205162 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Verafilcon A
Description: Daily disposable silicone hydrogel contact lenses indicated for the optical correction of refractive ametropia (myopia and hyperopia)
Study NCT04205162 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Etafilcon A
Description: Daily disposable silicone hydrogel contact lenses indicated for the optical correction of refractive ametropia (myopia and hyperopia)
Study NCT00684944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TRx0014
Description: Gelatin capsule, tid
Study NCT02300987 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LEE011
Study NCT02300987 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LEE011 Placebo
Study NCT01611415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipragliflozin
Description: Oral
Study NCT01611415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: Oral
Study NCT03078257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tirofiban in PV
Description: a loading dose of 10ug/kg tirofiban is given in 3 min through PV,followed by a maintenance dose of 0.15ug/kg\*min for 48h.~(clopidogrel 600 mg+aspirin( ASA) 300 mg)x1 day.
Study NCT03078257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tirofiban in IC
Description: a loading dose of 10ug/kg tirofiban is given in 3 min through IC,followed by a maintenance dose of 0.15ug/kg\*min for 48h.~(clopidogrel 600 mg+ ASA 300 mg)x1 day.
Study NCT03078257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antiplatelet thrombolysin
Description: a loading dose of 5 IU/60kg in 5 min through PV,followed by a maintenance dose of 0.002 IU/kg/h for 48h.~(clopidogrel 600 mg+ ASA 300 mg)x1 day.
Study NCT03078257 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: a loading dose of 5 IU/60kg in 5 min through PV,followed by a maintenance dose of 0.002 IU/kg/h for 48h.~(clopidogrel 600 mg+ ASA 300 mg)x1 day.
Study NCT03078257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: loading dose of 300 mg clopidogrel followed by a maintenance dose of 75 mg/d for at least 5 days
Study NCT03078257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: loading dose of 300 mg aspirin followed by a maintenance dose of 100 mg/d for at least 5 days.
Study NCT03078257 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Description: loading dose of 300 mg aspirin followed by a maintenance dose of 100 mg/d for at least 5 days.
Study NCT03078257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: loading dose of 600 mg clopidogrel followed by a maintenance dose of 75 mg/d for at least 5 days
Study NCT03078257 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clopidogrel
Description: loading dose of 600 mg clopidogrel followed by a maintenance dose of 75 mg/d for at least 5 days
Study NCT04611594 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fluid restriction
Description: Ingestion of approximately 20 ml / kg of ideal weight,
Study NCT03934060 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: specific strength training
Study NCT00981227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate
Description: Scored tablets
Study NCT00981227 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral route
Study NCT00485004 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cutting balloon
Description: Cutting balloon
Study NCT00485004 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cutting balloon
Description: Cutting balloon
Study NCT00485004 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent
Description: Sirolimus-eluting stent
Study NCT00485004 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus-eluting stent
Description: Sirolimus-eluting stent
Study NCT03212378 — intervention group
Intervention type: OTHER
Intervention: percutaneous coronary interventions
Description: Percutaneous coronary intervention.
Study NCT00891098 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Imaginal exposure
Description: 7 individual sessions of imaginal exposure of trauma memories according to the prolonged exposure treatment manual
Study NCT00891098 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imagery rescripting
Description: 7 individual sessions of imagery rescripting of trauma memories according to the imagery rescripting and reprocessing therapy manual
Study NCT01091766 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous injection of test solution
Description: test dose consists of 0.2 ml/kg body weight test solution of the assigned drug